|By PR Newswire||
|August 4, 2014 02:46 PM EDT||
MARLBOROUGH, Mass., Aug. 4, 2014 /PRNewswire/ -- Lemelson Capital Management, a private investment management firm, today announced that it has further increased its short position in Ligand Pharmaceuticals (NASDAQ: LGND) and updated with new information its June 16 and July 3, 2014 research reports on the stock.
- Lemelson Capital's original June 16, 2014 report can be found here.
- Lemelson Capital's appended 12-paged update, published on July 3, 2014, can be found here.
"Ligand's 76 percent plunge in EPS, reported in the company's Q2 earnings release this morning, is alarming, while the negative impact of new oral regimens on interferon use and, parenthetically, Promacta sales have not yet hit the P & L of Ligand or its partner Amgen," Lemelson Capital Management's Chief Investment Officer Emmanuel Lemelson said in releasing today's updated Ligand Pharmaceuticals report. "Key revenue programs such as collaborative research and development are also continuing their multi-year slide, while stock-based compensation has reached new highs, far in excess of the company's insipid earnings," he said.
Today's updated research report on Ligand Pharmaceuticals includes new material information that has been added to the firm's original June 16, 2014 research report. Today's report can be found here.
Disclosure: Lemelson Capital is currently short shares of LGND for its clients.
About Lemelson Capital Management:
Lemelson Capital Management, LLC is a private investment management firm focused on deep value and special situation investments. The firm's flagship fund, The Amvona Fund, has been named repeatedly one of the world's top performing hedge funds. For more information, see: http://www.lemelsoncapital.com
Chief Investment Officer
Lemelson Capital Management, LLC
SOURCE Lemelson Capital Management, LLC
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and 21st International Cloud Expo, which will take place in November in Silicon Valley, California.
Apr. 30, 2017 02:45 PM EDT Reads: 2,730
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
Apr. 30, 2017 02:45 PM EDT Reads: 1,244
Apr. 30, 2017 02:30 PM EDT Reads: 620
Apr. 30, 2017 02:30 PM EDT Reads: 1,012
Apr. 30, 2017 02:00 PM EDT Reads: 1,922
Apr. 30, 2017 02:00 PM EDT Reads: 877
Apr. 30, 2017 01:15 PM EDT Reads: 2,708
Apr. 30, 2017 01:15 PM EDT Reads: 3,166
Apr. 30, 2017 01:15 PM EDT Reads: 2,225
Apr. 30, 2017 01:00 PM EDT Reads: 1,072
Apr. 30, 2017 12:15 PM EDT Reads: 879
Apr. 30, 2017 12:00 PM EDT Reads: 1,394
Apr. 30, 2017 12:00 PM EDT Reads: 1,640
Apr. 30, 2017 12:00 PM EDT Reads: 1,929
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Apr. 30, 2017 11:30 AM EDT Reads: 2,450